Literature DB >> 14558083

Differential expression of HLA class II genes associated with disease susceptibility and progression in rheumatoid arthritis.

Christian Heldt1, Joachim Listing, Osman Sözeri, Franca Bläsing, Stefan Frischbutter, Brigitte Müller.   

Abstract

OBJECTIVE: Rheumatoid arthritis (RA)-associated HLA class II genes are assumed to promote susceptibility to and/or progression of the disease. Among the various modes of action proposed so far is the effect of the differential expression of HLA class II genes in different types of antigen-presenting cells on the Th1/Th2 balance. The aim of this study was to investigate the differential expression of genes encoded within the RA-associated HLA-DR4 superhaplotype and within the neutral DR7 and DR9 superhaplotypes.
METHODS: The promoters encoded within these 3 haplotypes were first analyzed for sequence polymorphisms. To test for functional consequences, we assumed that the binding of nuclear factors to the promoter elements was correlated with the transcription activity, and we used surface plasmon resonance technology. To that end, oligonucleotides representing the polymorphic regulatory sequences and nuclear extracts from a monocyte cell line and a B cell line were used.
RESULTS: While the promoters of the highly polymorphic HLA-DRB1*04, *07, and *09 alleles showed comparable binding of nuclear factors, differential binding was observed for the 2 promoters that drive the relatively nonpolymorphic DRB4 alleles in linkage disequilibrium with DRB1. Interestingly, analysis of RA patients positive for DR4, DR7, and DR9 revealed the segregation of radiographic progression with the stronger of the 2 DRB4 promoters, independent of the DRB1 allele. Moreover, DRB1*04 alleles in RA patients showed a reduced association with the DRB4 splice variant, completely preventing DRB4 expression.
CONCLUSION: Our findings represent the first evidence of a correlation between the differential expression of HLA class II genes and both the susceptibility and the progression of RA.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14558083     DOI: 10.1002/art.11251

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  7 in total

1.  The functional importance of sequence versus expression variability of MHC alleles in parasite resistance.

Authors:  Jan Axtner; Simone Sommer
Journal:  Genetica       Date:  2012-11-24       Impact factor: 1.082

2.  Role of the MHC2TA gene in autoimmune diseases.

Authors:  Alfonso Martínez; Marta Sánchez-Lopez; Jezabel Varadé; Ana Mas; M Carmen Martín; Virginia de Las Heras; Rafael Arroyo; Juan Luis Mendoza; Manuel Díaz-Rubio; Benjamín Fernández-Gutiérrez; Emilio G de la Concha; Elena Urcelay
Journal:  Ann Rheum Dis       Date:  2006-09-29       Impact factor: 19.103

Review 3.  The MHC2TA -168A/G polymorphism and risk for rheumatoid arthritis: a meta-analysis of 6861 patients and 9270 controls reveals no evidence for association.

Authors:  P G Bronson; L A Criswell; L F Barcellos
Journal:  Ann Rheum Dis       Date:  2007-09-17       Impact factor: 19.103

4.  Allelic combinations of promoter and exon 2 in DQB1 in dogs and wolves.

Authors:  Karin T Berggren; Jennifer M Seddon
Journal:  J Mol Evol       Date:  2008-06-27       Impact factor: 2.395

5.  Type 1 Diabetes Mellitus-Associated Genetic Variants Contribute to Overlapping Immune Regulatory Networks.

Authors:  Denis M Nyaga; Mark H Vickers; Craig Jefferies; Jo K Perry; Justin M O'Sullivan
Journal:  Front Genet       Date:  2018-11-21       Impact factor: 4.599

Review 6.  The Potential Role of Genomic Medicine in the Therapeutic Management of Rheumatoid Arthritis.

Authors:  Marialbert Acosta-Herrera; David González-Serna; Javier Martín
Journal:  J Clin Med       Date:  2019-06-10       Impact factor: 4.241

7.  Differences in Expression of Human Leukocyte Antigen Class II Subtypes and T Cell Subsets in Behçet's Disease with Arthritis.

Authors:  S M Shamsul Islam; Hyoun-Ah Kim; Bunsoon Choi; Ju-Yang Jung; Sung-Min Lee; Chang-Hee Suh; Seonghyang Sohn
Journal:  Int J Mol Sci       Date:  2019-10-11       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.